References
- Bonaglia, M. C., Giorda, R., Beri, S., De Agostini, C., Novara, F., Fichera, M., & Galesi, O. (2011). Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genetics, 7, e1002173.
- Choi, S. Y., Pang, K., Kim, J. Y., Ryu, J. R., Kang, H., Liu, Z., & Han, K. (2015). Post-transcriptional regulation of SHANK3 expression by microRNAs related to multiple neuropsychiatric disorders. MoleculaBrain, 8, 74.
- Cusmano-Ozog, K., Manning, M. A., & Hoyme, H. E. (2007). 22q13.3 deletion syndrome: A recognizable malformation syndrome associated with marked speech and language delay. American Journal of Medical Genetics, 145C, 393–398.
- Denayer, A., Van Esch, H., de Ravel, T., Frijns, J. P., Van Buggenhout, G., Vogels, A., & Swillen, A. (2012). Neuropsychopathology in 7 patients with the 22q13 deletion syndrome: Presence of bipolar disorder and progressive loss of skills. Molecular Syndromology, 3, 14–20.
- Egger, J. I., Zwanenburg, R. J., van Ravenswaaij-Arts, C. M., Kleefstra, T., & Verhoeven, W. M. (2016). Neuropsychological phenotype and psychopathology in seven adult patients with Phelan-McDermid syndrome: Implications for treatment strategy. Genes Brain and Behavior, 15, 395–404.
- Egger, J. I. M., Verhoeven, W. M. A., Groenendijk-Reijenga, R., & Kant, S. G. (2017). Phelan-McDermid syndrome due to SHANK3 mutation in an intellectually disabled adult male: Successful treatment with lithium. BMJ Case Reports, pii, bcr-2017–220778.
- Kolevzon, A., Angarita, B., Bush, L., Wang, A. T., Frank, Y., Yang, A., & Buxbaum, J. D. (2014). Phelan-McDermid syndrome: A review of the literature and practice parameters for medical assessment and monitoring. Journal of Neurodevelopmental Disorders, 6, 39.
- Messias, E., Kaley, S. N., & McKelvey, K. D. (2013). Adult-onset psychosis and clinical genetics: A case of Phelan-McDermid syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences, 25, E27.
- Pasini, A., D’Agati, E., Casarelli, L., & Curatolo, P. (2010). Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome. Brain & Development, 32, 425–427.
- Philippe, A., Craus, Y., Rio, M., Bahi-Buisson, N., Boddaert, N., Malan, V., & Robel, L. (2015). Case report: An unexpected link between partial deletion of the SHANK3 gene and Heller’s dementia infantilis, a rare subtype of autism spectrum disorder. BMC Psychiatry, 15, 256.
- Sarasua, S. M., Boccuto, L., Sharp, J. L., Dwivedi, A., Chen, C. F., Rollins, J. D., & DuPont, B. R. (2014). Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. Human Genetics, 133, 847–859.
- Serret, S., Thümmler, S., Dor, E., Vesperini, S., Santos, A., & Askenazy, F. (2015). Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: Case reports. BMC Psychiatry, 15, 107.
- Verhoeven, W. M., Egger, J. I., Cohen-Snuijf, R., Kant, S. G., & de Leeuw, N. (2013). Phelan-McDermid syndrome: Clinical report of a 70-year-old woman. AmericanJournal of MedicalGenetics, 161A, 158–161.
- Verhoeven, W. M., Egger, J. I., Willemsen, M. H., de Leijer, G. J., & Kleefstra, T. (2012). Phelan-McDermid syndrome in two adult brothers: Atypical bipolar disorder as its psychopathological phenotype? NeuropsychiatricDisease andTreatment, 8, 175–179.b.
- Vucurovic, K., Landais, E., Delahaigue, C., Eutrope, J., Schneider, A., Leroy, C., & Doco-Fenzy, M. (2012). Bipolar affective disorder and early dementia onset in a male patient with SHANK3 deletion. European Journal M Ed Genetics, 55, 625–629.